Literature DB >> 21890336

Clinical characteristics and possible phenotypes of an adult severe asthma population.

Regina Maria de Carvalho-Pinto1, Alberto Cukier, Luciene Angelini, Leila Antonangelo, Thais Mauad, Marisa Dolhnikoff, Klaus F Rabe, Rafael Stelmach.   

Abstract

BACKGROUND: Currently, there are no studies of well-characterized severe asthmatics in Brazil. We aimed to study a population of severe treated asthmatics still uncontrolled to characterize them and define possible phenotypes.
METHODS: Descriptive cross-sectional outpatient study of severe asthmatics, evaluating functional and inflammatory markers, health-related quality of life, anxiety and depression symptoms, clinical control status, and characteristics related to atopy, age of asthma onset, induced sputum eosinophil levels, and airflow limitation. We also grouped the subgroups characteristics to identify phenotypes. The study is registered on ClinicalTrial.gov NCT 01089322.
RESULTS: From 128 eligible patients with severe/uncontrolled asthma, 74 fulfilled the inclusion criteria. The cohort was comprised of 85% women, frequently with a body mass index higher than 31 kg m(-2), atopy (60%), early-onset disease (50%), sputum eosinophilia (80%), comorbidities, and reduced quality of life. Nonatopics had significant higher asthma onset (19 y.a.) and twice level of induced sputum eosinophil. Late-onset patients had significantly less atopy (57%) and higher levels of induced sputum eosinophils. Non-eosinophilics had lower levels of inflammatory markers. Patients with airflow limitation had more intensive care unit admissions (56%) and 1.5 times more airway resistance. Subgroups characteristics identified a priori four well-characterized phenotypes, with 55% presenting sputum eosinophilia.
CONCLUSION: Our data emphasize the high burden of disease, the persistence of inflammation and the existence of clinical possible phenotypes population sharing common features with published cohorts. Despite the necessity of further investigation into pathogenic mechanisms, this study with clinically difficult patient group may help to improve future asthma care.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890336     DOI: 10.1016/j.rmed.2011.08.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  13 in total

1.  CpG-ODNs and Budesonide Act Synergistically to Improve Allergic Responses in Combined Allergic Rhinitis and Asthma Syndrome Induced by Chronic Exposure to Ovalbumin by Modulating the TSLP-DC-OX40L Axis.

Authors:  Hong-Tao Li; Zhuang-Gui Chen; Yu-Sen Lin; Hui Liu; Jin Ye; Xiao-Ling Zou; Yan-Hong Wang; Hai-Ling Yang; Tian-Tuo Zhang
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

2.  Chronic traffic pollution exposure is associated with eosinophilic, but not neutrophilic inflammation in older adult asthmatics.

Authors:  Tolly G Epstein; Banurekha Kesavalu; Cheryl K Bernstein; Patrick H Ryan; Jonathan A Bernstein; Nives Zimmermann; Zana Lummus; Manuel S Villareal; Andrew M Smith; Peter H Lenz; David I Bernstein
Journal:  J Asthma       Date:  2013-10-01       Impact factor: 2.515

Review 3.  Omalizumab for severe asthma: efficacy beyond the atopic patient?

Authors:  Christian Domingo
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

4.  Cognitive behavioural therapy (CBT) for patients with chronic lung disease and psychological comorbidities undergoing pulmonary rehabilitation.

Authors:  Marsus I Pumar; Mark Roll; Pamela Fung; Tricia A Rolls; James R Walsh; Rayleen V Bowman; Kwun M Fong; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

5.  Glucocorticoid and estrogen receptors are reduced in mitochondria of lung epithelial cells in asthma.

Authors:  Davina C M Simoes; Anna-Maria G Psarra; Thais Mauad; Ioanna Pantou; Charis Roussos; Constantine E Sekeris; Christina Gratziou
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 6.  Management of the patient with eosinophilic asthma: a new era begins.

Authors:  Jantina C de Groot; Anneke Ten Brinke; Elisabeth H D Bel
Journal:  ERJ Open Res       Date:  2015-09-23

7.  Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic.

Authors:  Rodrigo Athanazio; Regina Carvalho-Pinto; Frederico Leon Arrabal Fernandes; Samia Rached; Klaus Rabe; Alberto Cukier; Rafael Stelmach
Journal:  BMC Pulm Med       Date:  2016-11-16       Impact factor: 3.317

8.  Effect of Hyssopus officinalis L. on inhibiting airway inflammation and immune regulation in a chronic asthmatic mouse model.

Authors:  Xiaojuan Ma; Xiumin Ma; Zhixing Ma; Jing Wang; Zhan Sun; Wenyan Yu; Fengsen Li; Jianbing Ding
Journal:  Exp Ther Med       Date:  2014-09-18       Impact factor: 2.447

9.  Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control.

Authors:  Regina Maria de Carvalho-Pinto; Rosana Câmara Agondi; Pedro Giavina-Bianchi; Alberto Cukier; Rafael Stelmach
Journal:  J Bras Pneumol       Date:  2017 Nov-Dec       Impact factor: 2.624

10.  Factors associated with asthma control: MOSAR study (Multicenter Observational Study of Asthma in Rabat-Morocco).

Authors:  Imane Ghanname; Ahmed Chaker; Abha Cherkani Hassani; Laila Herrak; Serge Arnaul Ebongue; Mustapha Laine; Khalid Rahhali; Abdelhak Zoglat; Aida Maria Benitez Rexach; Samir Ahid; Yahia Cherrah
Journal:  BMC Pulm Med       Date:  2018-04-24       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.